<SEC-DOCUMENT>0001193125-22-185071.txt : 20220629
<SEC-HEADER>0001193125-22-185071.hdr.sgml : 20220629
<ACCEPTANCE-DATETIME>20220629161819
ACCESSION NUMBER:		0001193125-22-185071
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220629
DATE AS OF CHANGE:		20220629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265812
		FILM NUMBER:		221054868

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d301089d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to 424 (b) (3) <BR> Registration Statement No. 333-265812 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,000,000 shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g301089g81b06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed resale from time to time of up to 4,000,000 shares (the &#147;Shares&#148;) of our common stock, par
value $0.0001 per share (the &#147;common stock&#148;), which are issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of common stock (the
<FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;), by the selling stockholder named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders&#146;
transferees, pledgees, donees or successors). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of the Shares from time to time by the selling
stockholder to satisfy the registration rights they were granted in connection with the issuance of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. We will not receive any proceeds from the sale of the Shares by the selling
stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder may offer and sell or otherwise dispose of the Shares described in this prospectus from time to time
through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholder will bear all underwriting fees, commissions and discounts, if any,
attributable to the sale of Shares and any transfer taxes. We will bear all other costs, expenses and fees in connection with the registration of the Shares. See &#147;Plan of Distribution&#148; for more information about how the selling stockholder
may sell or dispose of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#147;RAPT.&#148; On
June&nbsp;28, 2022, the closing price of our common stock was $18.02 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in shares of our common stock involves a
high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#147;<A HREF="#toc301089_3">Risk Factors</A>&#148; on page 5 of this prospectus and any similar section contained in the applicable
prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is June 29, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Page</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_7">SELLING STOCKHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_11">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc301089_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process. Under this shelf process, the selling stockholder may from time to time sell the Shares described in this prospectus in one or more offerings or otherwise as
described under &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may be supplemented from time to time by one or more prospectus
supplements. Such prospectus supplement may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the
information in the prospectus supplement. You should carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#147;Where You Can Find Additional Information&#148;
before deciding to invest in any Shares being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholder has authorized anyone to provide any
information other than that contained or incorporated by reference in this prospectus or in any related prospectus supplement or any free writing prospectus that we have authorized. We take no responsibility for, and can provide no assurance as to
the reliability of, any other information that others may give you. The Shares are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this
prospectus is accurate as of any date other than the respective dates of such document. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights important features of this offering and the information included or incorporated by reference in this prospectus.
This summary does not contain all of the information you should consider before investing in our common stock, par value $0.0001 per share (the &#147;common stock&#148;). You should carefully read this prospectus, any applicable prospectus
supplement and the information incorporated by reference in this prospectus and any applicable prospectus supplement before you invest in our common stock. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References in this prospectus to &#147;RAPT,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
RAPT Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries, if any, unless otherwise specified. When we refer to &#147;you,&#148; we mean the holders of common stock of the Company. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our proprietary drug discovery
and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. Our lead inflammation drug candidate, RPT193, and our lead oncology drug candidate, FLX475, each
target <FONT STYLE="white-space:nowrap">C-C</FONT> motif chemokine receptor 4, a drug target that potentially has broad applicability in inflammatory diseases and oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (&#147;Th2
cells&#148;) into inflamed tissues. Th2 cells are known to be drivers of inflammatory diseases, including atopic dermatitis (&#147;AD&#148;), asthma, chronic spontaneous urticaria (skin rash), allergic rhinitis, chronic rhinosinusitis and
eosinophilic esophagitis (inflammation of the esophagus). We believe RPT193, if approved, could fill an unmet medical need for a safe and well-tolerated oral drug in the treatment of allergic disorders. In June 2021, we announced positive topline
results from our randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD. After four weeks of treatment,
patients who received RPT193 showed greater improvement from baseline compared to the placebo group in several standard measures of disease severity, including the Eczema Area and Severity Index and the validated Investigator Global Assessment. In
the <FONT STYLE="white-space:nowrap">two-week</FONT> period following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo in these measures. We believe the results from this Phase 1b trial provide
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> (&#147;PoC&#148;) in AD and potentially additional <FONT STYLE="white-space:nowrap">Th2-driven</FONT> allergic indications. In May 2022, we
initiated our <FONT STYLE="white-space:nowrap">16-week</FONT> randomized placebo-controlled Phase 2b clinical trial of RPT193 as monotherapy in patients with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead oncology drug candidate,
FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors. We are conducting a Phase 1/2 clinical trial investigating FLX475 as a monotherapy and in combination with pembrolizumab (KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) to study the safety and potential clinical activity of FLX475 in patients with advanced cancer. In November 2020, we disclosed initial observations from the Phase 2 portion of the trial that
demonstrated clinical activity of FLX475 as a monotherapy as well as in combination with pembrolizumab. We believe these early initial observations establish initial clinical PoC for FLX475. As of June 2022, we are enrolling four expanded Stage 2
cohorts and one cohort is still enrolling in Stage 1. We are also enrolling a separate Phase 2 clinical trial investigating FLX475 in combination with ipilimumab (YERVOY<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with
melanoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We internally discovered and designed all our drug candidates utilizing what we refer to as our &#147;proprietary drug
discovery and development engine.&#148; Through our team&#146;s deep expertise in immunology and drug discovery, supported by advanced computational biology and proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> we are developing the
ability to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exploit difficult targets and generate drug candidates that we believe, if approved, will significantly improve treatment paradigms and outcomes for patients by fundamentally modulating the
immune responses in a range of inflammatory diseases and cancers. We continue to invest in our proprietary discovery and development engine and are pursuing a range of targets to generate additional potential drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Purchase
Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2022, we entered into a securities purchase agreement (the &#147;Securities Purchase Agreement&#148;) with
the institutional accredited investor named therein (the &#147;Investor&#148;), pursuant to which we agreed to issue and sell to the Investor in a private placement (the &#147;Private Placement&#148;)
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) to purchase an aggregate of 4,000,000 shares (the &#147;Shares&#148;) of the common stock. The Private
Placement closed on May&nbsp;27, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued to the Investor nor
the Shares were initially registered under the&nbsp;Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or any state securities laws. We have relied on the exemption from the registration requirements of the&nbsp;Securities
Act&nbsp;by virtue of Section&nbsp;4(a)(2) thereof and Rule&nbsp;506&nbsp;of&nbsp;Regulation D&nbsp;thereunder. In connection with the Investor&#146;s execution of the Purchase Agreement, the Investor represented to us that it is an &#147;accredited
investor&#148; as defined in&nbsp;Regulation D&nbsp;of the&nbsp;Securities Act&nbsp;and that <FONT STYLE="white-space:nowrap">the&nbsp;Pre-Funded&nbsp;Warrants</FONT> purchased by it were acquired solely for its own account and for investment
purposes and not with a view to the future sale or distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2022, in connection with the Private Placement, we entered into a registration rights agreement (the &#147;Registration Rights
Agreement&#148;) with the Investor, pursuant to which we agreed to (i)&nbsp;register the Shares for resale, (ii)&nbsp;use our commercially reasonable efforts to cause such registration statement to be declared effective within the timeframe set
forth in the Registration Rights Agreement and (iii)&nbsp;use our commercially reasonable efforts to keep such registration statement effective during the timeframe set forth in the Registration Rights Agreement. The Company has agreed to be
responsible for all reasonable fees and expenses incurred in connection with the registration of the registrable securities under the Registration Rights Agreement. Additionally, the Company has agreed to indemnify the selling stockholder for
losses, claims, damages or liabilities, joint or several, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any registration statement, subject to certain
exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that such registration statement is not filed or declared effective within the timeframe set forth in the
Registration Rights Agreement or any such effective registration statement subsequently becomes unavailable, we would be required to pay liquidated damages to the Investor equal to 1% of the aggregate amount invested by the Investor in the
Registrable Securities <FONT STYLE="white-space:nowrap">per&nbsp;30-day&nbsp;period</FONT> or pro rata for any portion thereof following the date by which such registration statement should have been filed or effective, as applicable, subject to
certain caps set forth in the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus is a part relates to the
offer and resale of the Shares. When we refer to the selling stockholder in this prospectus, we are referring to the Investor named in this prospectus as the selling stockholder and, as applicable, any donees, pledgees, assignees, transferees or
other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling Shares received after the date of this prospectus from the selling stockholder as a gift, pledge or other <FONT
STYLE="white-space:nowrap">non-sale</FONT> related transfer. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RAPT Therapeutics, Inc., was incorporated under the laws of the State of Delaware in March 2015 under the name FLX Bio, Inc. Our executive
offices are located at 561 Eccles Avenue, South San Francisco, California 94080. The telephone number at our executive office is&nbsp;(650) <FONT STYLE="white-space:nowrap">489-9000.&nbsp;Our</FONT> corporate website address is www.rapt.com. We do
not incorporate the information contained on, or accessible through, our website into this prospectus, and you should not consider it part of this prospectus. Our website address is included in this prospectus as an inactive textual reference only.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion of revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an emerging growth company until December&nbsp;31, 2024 (the end of the fiscal year following the fifth anniversary of our initial public offering) or until
such earlier time as we have more than $1.07&nbsp;billion in annual revenue, the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700&nbsp;million as of the last business day of our most recently
completed second fiscal quarter or we issue more than $1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely
on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> was less than $700&nbsp;million measured on the last business day of our most recently completed second fiscal quarter, and our annual revenue was less than $100&nbsp;million during our most
recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million measured on the last
business day of our second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other
public companies that are not smaller reporting companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock Offered by the Selling Stockholder </B></P></TD>
<TD>4,000,000 Shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P></TD>
<TD>We will not receive any of the proceeds from the sale of the Shares in this offering. The selling stockholder will receive all of the proceeds from the sale of the Shares hereunder. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P></TD>
<TD>An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under &#147;Risk Factors&#148; on page 5 of this prospectus and under similar headings in the other documents that
are incorporated by reference herein, as well as the other information included in or incorporated by reference in this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Symbol </B></P></TD>
<TD>Our common stock is listed on the Nasdaq Global Market the symbol &#147;RAPT.&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should
consider carefully the specific risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus,
the documents incorporated by reference, any prospectus supplement and any free writing prospectus that we may authorize. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not
presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial
condition, results of operations and cash flow could be materially and adversely affected. In that case, the trading price of our common stock could decline and you might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain forward-looking statements that
involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in the
prospectus and the documents we have filed with the SEC that are incorporated by reference that are not purely historical are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148;
&#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative of those terms, and similar expressions that convey uncertainty of future
events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements may include, but are not limited
to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, cost, timing, progress and results of research and development activities, preclinical or and
clinical trials with respect to RPT193, FLX475 and potential future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, develop and commercialize drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance RPT193, FLX475 or other future drug candidates into, and successfully complete,
preclinical studies and clinical or field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of RPT193, FLX475 or other future drug candidates, and any
related restrictions, limitations and/or warnings in the label of an approved drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and expand our drug discovery and development engine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify drug candidates using our drug discovery and development engine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection for our technology and any of our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize any of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of any of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and international jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability lawsuits and penalties related to our technology, our drug candidates and our current and
future relationships with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage the growth of our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately
under those arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively with existing competitors and new market entrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding uses of proceeds from our initial public offering and our <FONT
STYLE="white-space:nowrap">follow-on</FONT> offerings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential effects of extensive government regulation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements as predictions of future events. We discuss
in greater detail many of these risks in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments
thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document
containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, together with the documents we have filed with the SEC that are incorporated by reference, any prospectus
supplement and any free writing prospectus that we may authorize completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing
documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of the Shares in this offering. The selling stockholder will receive all of the proceeds
from the sale of the Shares hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary description of our capital stock is based on the provisions of our amended and restated certificate of incorporation
and amended and restated bylaws and the applicable provisions of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). This information is qualified entirely by reference to the applicable provisions of our amended and
restated certificate of incorporation and amended and restated bylaws. For information on how to obtain copies of our amended and restated certificate of incorporation and amended and restated bylaws, which are exhibits to the registration statement
of which this prospectus is a part, see the sections titled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 500,000,000 shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred stock, $0.0001 par value per share. A description of material terms and provisions of our amended and restated certificate of
incorporation and amended and restated bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and is qualified in its entirety by reference to our amended and restated certificate of
incorporation and amended and restated bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a
vote of the stockholders, including the election of directors. The amended and restated certificate of incorporation and amended and restated bylaws do not provide for cumulative voting rights in connection with election of directors unless, at the
time of such election, we are subject to Section&nbsp;2115(b) of the California General Corporation Law. The affirmative vote of holders of 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class,
will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, and removal of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends.</I> Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of outstanding shares of
common stock may receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. We have never issued a dividend on shares of our common stock and have no intention to do so in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation.</I> In the event we liquidate, dissolve or wind up, the assets legally available for distribution shall be distributed
ratably to the holders of shares of common stock and preferred stock, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences.</I> Holders of common stock have no preemptive, conversion or subscription rights, and there are no redemption or
sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that
we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and Nonassessable.</I> All outstanding shares of common stock are fully paid and
nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 50,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to
fix the designation, powers, preferences and rights of the shares of each series </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any of its qualifications, limitations or restrictions. Our board of directors can also increase or decrease the number of shares of any series, but not below the number of shares of that
series then outstanding, without any further vote or action by the Company&#146;s stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or
other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring,
discouraging or preventing a change in control of RAPT and may adversely affect the market price of RAPT&#146;s common stock and the voting and other rights of the holders of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2022, we entered into the Securities Purchase Agreement with the Investor, pursuant to which we agreed to issue and sell to the
Investor in the Private Placement <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase an aggregate of 4,000,000 shares of common stock. <FONT STYLE="white-space:nowrap">Each&nbsp;Pre-Funded&nbsp;Warrant</FONT> has an exercise
price of $0.0001 per Share. <FONT STYLE="white-space:nowrap">The&nbsp;Pre-Funded&nbsp;Warrants</FONT> are exercisable at any time after their original issuance and will not expire. The Private Placement closed on May&nbsp;27, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued in the Private Placement provide that the holder of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will not have the right to exercise any portion of its <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants if such holder, together with its affiliates, would beneficially own in excess
of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise (the &#147;Beneficial Ownership Limitation&#148;); provided, however, that the holder may increase or decrease the Beneficial Ownership
Limitation by giving 61 days&#146; notice to the Company, but not to any percentage in excess of 19.99%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants must pay the exercise price in cash upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, unless such holders are utilizing the cashless exercise provision of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants may be exercised (in the sole discretion of the holder), in whole or in part, at such time by means of a &#147;cashless
exercise&#148; in which the holder of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants shall be entitled to receive that number of Shares determined according to the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>[(A-B)*(X)]</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A = the VWAP (as defined
below) on the trading day immediately preceding the date of such election; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B = the exercise price then in effect; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = the number of Shares for which the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are being exercised (which shall include
both the number of Shares issued to the holder thereof and the number of Shares subject to the portion of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants being cancelled in payment of the exercise price). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used above, the &#147;VWAP&#148; means, for any date, the price determined by the first of the following clauses that applies: (i)&nbsp;if
the common stock is then listed on the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or the New York Stock Exchange (such market, the &#147;Trading Market&#148;), the daily volume-weighted average price of the
common stock for such date (or the nearest preceding date) on the Trading Market as reported by Bloomberg Financial L.P. (based on a &#147;Trading Day&#148; from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (ii) the volume-weighted average
price of the common stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (iii)&nbsp;if the common stock is not then listed on a Trading Market or quoted on the OTC Bulletin Board and if prices for the common stock are then
reported in the &#147;Pink Sheets&#148; published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting prices), the most recent bid price per share of the common stock so reported; or (iv)&nbsp;in all other cases, the fair market value of a share of common stock as determined by a good
faith determination of the Company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to apply for listing of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants on any securities exchange or other trading system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Registration Rights
Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;27, 2022, in connection with the Private Placement, we entered into the Registration Rights Agreement with the
Investor, pursuant to which we agreed to (i)&nbsp;register the Shares for resale, (ii)&nbsp;use our commercially reasonable efforts to cause such registration statement to be declared effective within the timeframe set forth in the Registration
Rights Agreement and (iii)&nbsp;use our commercially reasonable efforts to keep such registration statement effective during the timeframe set forth in the Registration Rights Agreement. The Company has agreed to be responsible for all reasonable
fees and expenses incurred in connection with the registration of the registrable securities under the Registration Rights Agreement. Additionally, the Company has agreed to indemnify the selling stockholder for losses, claims, damages or
liabilities, joint or several, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any registration statement, subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that such registration statement is not filed or declared effective within the timeframe set forth in the Registration Rights
Agreement or any such effective registration statement subsequently becomes unavailable, we would be required to pay liquidated damages to the Investor equal to 1% of the aggregate amount invested by the Investor in the Registrable Securities <FONT
STYLE="white-space:nowrap">per&nbsp;30-day&nbsp;period</FONT> or pro rata for any portion thereof following the date by which such registration statement should have been filed or effective, as applicable, subject to certain caps set forth in the
Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus is a part relates to the offer and resale of the
Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of incorporation and bylaws</I>. Our amended and restated certificate of incorporation and amended and restated bylaws include a
number of provisions that may deter or impede hostile takeovers or changes of control or management. These provisions include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of undesignated preferred stock.</I> Our board of directors has the authority, without further action by the stockholders, to
issue up to 50,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables
our board of directors to make it more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Board of directors vacancies.</I> Our amended and restated certificate of incorporation and amended and restated bylaws authorize only our
board of directors to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a
stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder action; special meetings of stockholders.</I> Our amended and restated certificate of incorporation provides that our
stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. Stockholders will not be permitted to cumulate their votes for the election
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of directors unless required by applicable law. Our amended and restated bylaws provide that only the chairman of our board of directors, chief executive officer or a majority of our board of
directors may call special meetings of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;203 of the DGCL. </I>We are subject to
Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in a business combination with any interested stockholder for a period of three years following the date the person became an interested stockholder, with the
following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested holder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (a)&nbsp;by persons who are directors and also officers and (b)&nbsp;pursuant to employee stock plans in which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines business combination to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines an &#147;interested
stockholder&#148; as an entity or person who, together with the entity&#146;s or person&#146;s affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the time of determination of
interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its certificate of incorporation. We have not
opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer
Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Global Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market the symbol &#147;RAPT.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_7"></A>SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have prepared this prospectus to allow the selling stockholder to offer and sell from time to time up to 4,000,000 Shares issuable upon the
exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by the selling stockholder. For a description of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, see &#147;Description of Capital <FONT
STYLE="white-space:nowrap">Stock&#151;Pre-Funded</FONT> Warrants.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of the Shares held by the
selling stockholder to satisfy certain registration obligations that we granted the selling stockholder in connection with the purchase of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Pursuant to a Registration Rights Agreement,
we have agreed to use commercially reasonable efforts to keep the registration statement, of which this prospectus is a part, effective until the earliest to occur of: (i)&nbsp;the date that all registrable securities covered by such registration
statement have been sold and (ii)&nbsp;the date on which all registrable securities covered by such registration statement may be sold without restriction pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth (i)&nbsp;the name of the selling stockholder, (ii)&nbsp;the number of shares beneficially owned by the selling
stockholder, including the Shares, (iii)&nbsp;the number of Shares that may be offered under this prospectus and (iv)&nbsp;the number of shares of our common stock that would be beneficially owned by the selling stockholder assuming all of the
Shares covered hereby are sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or
investment power with respect to our common stock. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the holder named in the table below has sole voting and investment power with respect to all
shares of common stock that they beneficially own, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder may sell some,
all or none of its Shares offered by this prospectus from time to time. We do not know how long the selling stockholder will hold the Shares covered hereby before selling them and we currently have no agreements, arrangements or understandings with
the selling stockholder regarding the sale or other disposition of any Shares. The information set forth in the table below is based on 29,646,821 shares of our common stock outstanding as of June&nbsp;16, 2022 and assumes the selling stockholder
disposes of all of the Shares covered by this prospectus and does not acquire beneficial ownership of any additional shares of common stock. The registration of the Shares does not necessarily mean that the selling stockholder will sell all or any
portion of the Shares covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this prospectus, the term &#147;selling stockholder&#148; includes the
selling stockholder listed in the table below, together with any additional selling stockholders listed in a prospectus supplement, and their donees, pledgees, assignees, transferees, distributees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that receive Shares in any <FONT STYLE="white-space:nowrap">non-sale</FONT> transfer after the date of this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned<BR>prior&nbsp;to&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Being&nbsp;Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common<BR>Stock&nbsp;Beneficially&nbsp;Owned<BR>after&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of<BR>Outstanding<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of<BR>Outstanding<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Redmile Group, LLC(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,199,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">817,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares registered for resale consist of Shares underlying the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase 4,000,000 shares of common stock held by Redmile Biopharma Investments III, L.P. (&#147;RBI III&#148;). The remaining shares listed under &#147;Shares of Common Stock
Beneficially Owned prior to this Offering&#148; and &#147;Shares of Common Stock Beneficially Owned after this Offering&#148; consist of 817,832 shares of common stock owned by a private investment vehicle (together with RBI III, the &#147;Redmile
Funds&#148;) managed by Redmile Group, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
LLC (the &#147;Redmile Group&#148;), which shares of common stock may be deemed beneficially owned by Redmile Group as investment manager of such private investment vehicle. The <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants may not be exercised if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder together with such holder&#146;s affiliates, would
exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise (the &#147;Beneficial Ownership Limitation&#148;); provided, however, that the holder may increase or decrease the Beneficial Ownership
Limitation by giving 61 days&#146; notice to the Company, but not to any percentage in excess of 19.99%. The &#147;Shares of Common Stock Beneficially Owned prior to this Offering&#148; column excludes an aggregate of 1,618,170 Shares issuable upon
the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants described above, which would not be exercisable within 60 days of June&nbsp;16, 2022 by virtue of the Beneficial Ownership Limitation described above. Redmile Group is
the investment manager to each of the Redmile Funds and, in such capacity, exercises voting and investment power over all of the securities held by the Redmile Funds and may be deemed to be the beneficial owner of these securities. Jeremy C. Green
serves as the principal of Redmile Group and also may be deemed to be the beneficial owner of these shares. Redmile Group and Mr.&nbsp;Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in
such shares, if any. The address of the Redmile Funds and Mr. Green is c/o Redmile Group, LLC, One Letterman Drive, Building D, Suite <FONT STYLE="white-space:nowrap">D3-300,</FONT> San Francisco, California 94129. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the Shares to permit the resale of the Shares by the selling stockholder from time to time after the date of this
prospectus upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. We will not receive any of the proceeds from the sale by the selling stockholder of the Shares. We will bear all fees and expenses incident to our
obligation to register the Shares, except that, if the Shares are sold through underwriters or broker-dealers, the selling stockholder will be responsible for underwriting discounts or commissions or agent&#146;s commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder may sell all or a portion of the Shares beneficially owned by them and offered hereby from time to time directly or
through one or more underwriters, broker-dealers or agents. The Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the
time of sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing of options, whether such options are listed on an options exchange or otherwise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the Shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the selling stockholder;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales pursuant to Rule 144 of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholder to sell a specified number of such Shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the selling stockholder effects such transactions by selling Shares to or through underwriters, broker-dealers or agents, such
underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of the Shares for whom they may act as agent or to whom they may sell as
principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the Shares or otherwise, the
selling stockholder may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling stockholder may also sell Shares short and deliver
Shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholder may also loan or pledge Shares to broker-dealers that in turn may sell such Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder may pledge or grant a security interest in some or all of the Shares
owned by it and, if the selling stockholder defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the Shares from time to time pursuant to this prospectus or other applicable provisions of the
Securities Act, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholder also may transfer and donate the
Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder and any broker-dealer participating in the distribution of the Shares may be deemed to be &#147;underwriters&#148;
within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular
offering of the Shares is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of shares of our common stock being offered and the terms of the offering, including the name or names of any
broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholder and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, the Shares may only be sold in such states through registered or licensed brokers or dealers. In
addition, in some states the Shares may not be sold unless such Shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the selling stockholder will sell any or all of the Shares registered pursuant to the registration statement,
of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholder and any other person participating in such distribution will be subject to
applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Shares by the selling stockholder
and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to our common stock. All of the foregoing may affect the
marketability of our common stock and the ability of any person or entity to engage in market-making activities with respect to our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the Shares pursuant to the registration statement of which this prospectus forms a part,
including, without limitation, SEC filing fees and expenses of compliance with state securities or &#147;blue sky&#148; laws; provided, however, that the selling stockholder will pay all underwriting discounts and selling commissions, if any. We
will indemnify the selling stockholder against liabilities, including some liabilities under the Securities Act, or the selling stockholder will be entitled to contribution. We may be indemnified by the selling stockholder against civil liabilities,
including liabilities under the Securities Act, that may arise from any written information furnished to us by the selling stockholder specifically for use in this prospectus or we may be entitled to contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once sold under the registration statement of which this prospectus forms a part, the Shares will be freely tradable in the hands of persons
other than our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, Chicago, Illinois, will pass upon the validity of the Shares offered hereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_11"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;we</FONT> filed with the SEC
under the&nbsp;Securities Act&nbsp;and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be
complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document.
Because we are subject to the information and reporting requirements of the&nbsp;Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.rapt.com. We do not incorporate the information
contained on, or accessible through, our website into this prospectus, and you should not consider it part of this prospectus. Our website address is included in this prospectus as an inactive textual reference only. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc301089_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed
with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No.&nbsp;001-38997): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38997)</FONT> for the fiscal year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;10, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000156459022009488/rapt-10k_20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2021 from our Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000119312522101064/d339320ddefa14a.htm">Schedule 14A</A>, filed
with the SEC on April&nbsp;11, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000156459022019387/rapt-10q_20220331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarter ended March&nbsp;31, 2022, filed with the SEC on May&nbsp;11, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather
than filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000119312522156862/d294886d8k.htm">May&nbsp;
23, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000119312522160964/d353637d8k.htm">May&nbsp;
26, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1673772/000119312522163962/d310238d8k.htm">May&nbsp;31, 2022</A>; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock, which is contained in a registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000119312519199060/d779692d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> on July&nbsp;22, 2019 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38997)</FONT> under the Exchange Act, including any amendment or report filed for the purpose of updating such description,
including <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm">Exhibit 4.2</A> to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-38997)</FONT> for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;30, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this
prospectus is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until we file a
post-effective amendment that indicates the termination of the offering of the Shares made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings
updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated
or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RAPT Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:
Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">561 Eccles Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">South San Francisco, California 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">489-9000</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>4,000,000 shares </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g301089g81b06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g301089g81b06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g301089g81b06.jpg
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ME>%*<+%B.>"\C_ \<\ <\'@#L!ZDD_/C7MB9[DRA0>"0D:?$<\<D\?$GN3\
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M:H5&H]CXK+8R7*5XX(LME<.R3"4V,3)3CL2 (Z>3(UVE>C,)+AR%B1^N-")
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M'=]I8:_0P>U\A:M9+.0WK.?RU/'S=%7V9]TC@2[GL2KQH)YR[0Q2\,P$C@E
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M1[G=D[-;W[-1&HB)YL"-(L/E51>D-O?Q$D(Y)Y>7?>X99&Y))]YW9N/0<\*
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9C &2H\DCR2R23332R2333222RR/([,?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
